Anticoagulation for AF
Interactive Tool to Guide Management of Anticoagulation in AF for Primary Care using the 2023 Guideline Update

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: November 15, 2024

Expiration: November 14, 2025

About This Tool & Disclaimer

Interactive Tool to Guide Management of Anticoagulation in AF for Primary Care Using the 2023 Guideline Update

 Clinical Care Options, LLC, is grateful to expert faculty, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in November 2024, and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on making optimal management choices for anticoagulation in AF using the 2023 ACC/AHA/ACCP/HRS guidelines.

A series of questions allows the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include CHA2DS2-VASc score, additional stroke risk factors, bleeding risk, renal function, and weight.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for anticoagulation in patients with AF. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate for making management decisions.

This tool assumes we have a “standard” patient with AF but with no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display guideline-based recommendations for that specific patient case.

For additional information on best practices in the management of patients with AF, please see our online module titled, Tools of the Trade: Implementing New Guidelines for NVAF Management and Treatment in Primary Careauthored by Alpesh N. Amin, MD, MBA, MACP, MHM, FRCP (Lond), FACC, FHFSA, CPE; Christopher B. Granger, MD; and Andrea Natale, MD, FHRS, FACC, FESC, FAPHRS.

This program is supported by an educational grant from Bristol Myers Squibb.

 The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Alpesh N. Amin, MD, MBA, MACP, MHM, FRCP (Lond), FACC, FHFSA, CPE: consultant/advisor/speaker: Alexion, Aseptiscope, AstraZeneca, Bayer, Dexcom, Ferring, Gilead, GlaxoSmithKline, Lilly, Novo Nordisk, Pfizer, Renibus, Reprieve, Salix, Seres, Spero.

Christopher B. Granger, MD: consultant/advisor/speaker: AbbVie, Abiomed, Alnylam, Anthos, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardionomic, Cadrenal, CeleCore Therapeutics, HengRui, Janssen, Medtronic, Merck, Novo Nordisk, Novartis, Pfizer, Philips, REATA, Roche, Veralox; researcher: Alnylam, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Philips, Roche.

Andrea Natale, MD, FHRS, FACC, FESC, FAPHRS: consultant/advisor/speaker: Abbott, Biosense Webster, Biotronik, Boston Scientific, iRhythm, Medtronic.

© 2024 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Tool to Guide Management of NVAF in Primary Care Using the 2023 Guideline Update” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal anticoagulation management choices for treating individuals with AF. The information provided is based on the 2023 ACC/AHA/ACCP/HRS guideline recommendations.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Tool to Guide Management of NVAF in Primary Care Using the 2023 Guideline Update” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content